Advanced Glycation End Products Market: Introduction
According to the report, the global advanced glycation end products market was valued at US$ 1.56 Bn in 2020. It is projected to expand at a CAGR of 5.4% from 2021 to 2031. Advanced glycation end products (AGEs) are a group of compounds that are usually developed via non-enzymatic reactions that occur between the carbonyl groups of reducing sugars & the free lipids, amino groups of proteins, or nucleic acids. They could be derived exogenously from diet or by endogenously inside the body. Advanced glycation end products form intracellular and extracellular inside every tissues and body fluids and are capable of cross-linking with other proteins, which can affect their normal mechanism or functions.
Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81706
The advanced glycation end products market has been segmented based on type, indication, end user, and region. Based on type, the market can be categorized into non-fluorescent AGEs, fluorescent AGEs, and others. The fluorescent AGEs segment can be further sub-segmented into Pentosidine and Methylglyoxal-lysine dimer (MOLD). The non-fluorescent AGEs segment can be further split into Carboxymethyl-lysine (CML), Carboxyethyl-lysine (CEL), and Pyrraline. Based on end user, the market has been classified into hospitals, specialty clinics, and others. In terms of application, the market has been categorized into diabetes complications, cancer, bone diseases, neurodegenerative diseases, and others.
The rise in incidence of cancer globally is driving the market, as advanced glycation end products majorly raise the levels of inflammation in the body, which has been associated with the development of cancer. For instance, according to the National Cancer Institute, 2019, an estimated 1,762,450 new cases of cancer were diagnosed, globally, with around 606,880 deaths from the disease.
AGEs Significant in Pathogenesis of Various Disorders
Protein glycation and formation of advanced glycation end-products (AGEs) play an important role in the pathogenesis of diabetic complications such as retinopathy, nephropathy, neuropathy, and cardiomyopathy. Several research studies have suggested that advanced glycation end products is one of the key factors in the development of metabolic memory in diabetic complications, as AGEs are produced and accumulated irreversibly in the body, depending on the degree of blood sugar regulation and duration. According to the International Diabetes Federation, the global diabetes prevalence was estimated to be 9.3% (463 million people) in 2019, which is likely to increase to 10.2% (578 million) by 2030. Hence, the rise in prevalence of diabetes is a key factor that is likely to drive the demand for treatment and diagnosis of advanced glycation end product-related disorders.
Request for Analysis of COVID19 Impact on Advanced Glycation End Products Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81706
Non-fluorescent AGEs to Dominate Global Market
In terms of type, the global advanced glycation end products market has been classified into non-fluorescent AGEs, fluorescent AGEs, and others. The fluorescent AGEs segment can be further sub-segmented into Pentosidine and Methylglyoxal-lysine dimer (MOLD). The non-fluorescent AGEs segment can be further split into Carboxymethyl-lysine (CML), Carboxyethyl-lysine (CEL), and Pyrraline. The non-fluorescent AGEs segment dominated the global advanced glycation end products market in 2020, and the trend is likely to continue during the forecast period.
In non-fluorescent AGEs, Carboxymethyl-lysine (CML) modification of proteins is one of the major glycoxidation products formed in vitro by the reaction between glucose and protein. According to a report by BMC Journal 2018, among different types of AGEs, CML has been found as the most abundant AGEs in human plasma.
The increase in global prevalence of diabetes has increased investigation of Carboxymethyl-lysine (CML) levels in serum of the ischemic heart disease patients with and without Type 2 diabetes. As the complex compound of non-fluorescent AGEs, (CML) further lead to more complication in diabetic patients. This makes the segment dominant.
Request a Sample of Advanced Glycation End Products Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=81706
Diabetic Complications Important Application Area
Based on application, the global advanced glycation end products market has been categorized into diabetes complications, cancer, bone diseases, neurodegenerative diseases, and others. The diabetes complications segment dominated the global advanced glycation end products market in 2020. In 2017, around 462 million individuals were affected by type 2 diabetes, constituting 6.28% of the world’s population. Protein glycation and formation of advanced glycation end products (AGEs) play an important role in the pathogenesis of diabetic complications such as retinopathy, nephropathy, and neuropathy.
Recent findings suggest that N-(ε)-CML AGEs are key modulators for the development of nonproliferative retinopathy among type 2 diabetic patients. Hence, the demand for anti-AGEs compounds such as pyridoxamine and aminoguanidine is increasing.
Hospitals to be Promising End User
In terms of end user, the global advanced glycation end products market has been classified into hospitals, specialty clinics, and others. The hospitals segment dominated the market in 2020. The segment is expected to expand at a prominent CAGR from 2021 to 2031. The expansion of the segment can be attributed to a high number of patient footfalls and treatment of chronic illness performed in large and specialized hospitals, which are able to provide treatment services with available trained professionals. Additionally, the number of hospitals is increasing in regions such as Asia Pacific and the Middle East, which propels the segment.
Enquiry before Buying Advanced Glycation End Products Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=81706
North America to Lead Advanced Glycation End Products Market
The global advanced glycation end products market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2020, followed by Europe. North America is anticipated to be a highly lucrative market for advanced glycation end products owing to the presence of prominent biopharmaceutical players in the region. The rapid approval of biopharmaceutical products by regulatory agencies is also fueling the advanced glycation end products market in the region. However, the market in Asia Pacific is estimated to expand at a rapid pace, owing to the presence of significant generic manufacturers and focus of major players on the region. The expansion of pharmaceutical and biopharmaceutical industries has led to the rapid demand for advanced glycation end products in the region. Additionally, investments by Contract Research Organizations (CROs) for the development of drugs and biologics are anticipated to drive the advanced glycation end products market in Asia Pacific.
The global advanced glycation end products market is fragmented due to the presence of large number of leading players. Key players operating in the global market include AbbVie, Inc. (Allergan Plc), Merck KGaA, Takeda Pharmaceutical Company Limited, Estée Lauder Companies, Shiseido Company, Limited, Beiersdorf AG, L’Oreal S.A., NuFACE, Rodan & Fields, PhotoMedex, Inc., Ostium Cosmetics, Cell Biolabs, Inc., and Shanghai Korain Biotech Co., Ltd. New product development through robust R&D activities and mergers & acquisitions are the key strategies adopted by these players to expand business in the global advanced glycation end products market.
More Trending Reports by Transparency Market Research:
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
USA – Canada Toll Free: 866-552-3453